OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.
- 60% increase in dose sales year-on-year
- 56% growth in commercially active centres
- Germany G-BA trial set to start in Q4 FY26
- Operational cost savings of $3.4-3.9 million annualised
- New Sydney manufacturing facility on track for 1H FY27
Dose Sales and Market Expansion Drive Momentum
OncoSil Medical (ASX:OSL) posted a striking 60% jump in dose sales in the third quarter of FY26 compared to the prior year, signalling growing clinical adoption of its targeted radiotherapy device for unresectable locally advanced pancreatic cancer. Revenue climbed 49% year-on-year, while the number of commercially active treatment centres surged 56% to 28, reflecting broader market penetration across key territories including Europe and Türkiye.
This surge builds on earlier momentum from the first half of FY26, where dose sales had already doubled, underscoring the company’s accelerating commercial footprint. The expansion into new centres such as Vivantes Neukölln Hospital in Berlin and Acibadem Maslak Hospital in Türkiye highlights increasing physician acceptance and OncoSil’s strategic push into high-volume pancreatic cancer treatment hubs. The company’s CEO Nigel Lange emphasised that these developments demonstrate a "continued expansion in clinical adoption and our commercial footprint across key markets." The roll-out is also supported by encouraging real-world data from early clinical use in Türkiye showing high surgical conversion rates, where 83% of treated patients proceeded to successful resection, a significant improvement on typical outcomes.
Clinical Trials and Regulatory Milestones in Sight
OncoSil is advancing several pivotal clinical programs that could broaden its market access and label indications. The fully funded Germany Federal Joint Committee (G-BA) trial remains on track for initiation in Q4 FY26, representing a crucial step toward reimbursement in one of Europe’s largest pancreatic cancer markets. The company estimates this trial could add $47.1 million in value over its lifetime. Preparations include training and equipping participating centres to ensure rapid patient enrolment, targeting the top 50 German pancreatic cancer centres that perform nearly half of the country's complex pancreatic surgeries.
The TRIPP-FFX trial, evaluating OncoSil combined with FOLFIRINOX chemotherapy, recently completed its last patient last visit milestone, with results expected in Q4 FY26. These data are anticipated to support a regulatory submission planned for the second half of calendar 2026, potentially expanding OncoSil’s approved use alongside standard chemotherapy regimens. Concurrently, the PANCOSIL study is progressing toward regulatory submission, aiming to enable a percutaneous delivery method that could significantly widen clinician adoption by including Interventional Radiologists and allowing outpatient procedures.
Manufacturing and Cost Efficiency Initiatives
OncoSil is also preparing to bolster its supply chain and cost structure with a new manufacturing facility in Sydney’s Macquarie Park, expected to be fully operational in the first half of FY27. This facility is designed to reduce the cost of goods sold materially, improve supply resilience, and support scaling commercial demand. The company has completed successful test runs and is progressing through ISO 13485 certification and regulatory audits.
Alongside manufacturing upgrades, OncoSil has implemented strategic operational changes expected to lower its annual cost base by $3.4 to $3.9 million from FY27 onwards. This includes streamlining corporate functions and winding down clinical trials nearing completion. Notably, Renzo DeCarlo, formerly Head of Transformation, has been appointed Global Head of Manufacturing and Operations, agreeing to receive his entire remuneration as equity at a premium to market price, reflecting a commitment to cost discipline and shareholder alignment.
Financial Position Strengthened by Capital Raise and R&D Incentives
Financially, OncoSil closed the quarter with $9.3 million in cash, bolstered by an $8 million capital raise completed earlier in the year and a $1.8 million R&D tax incentive refund. Customer receipts for the quarter increased 158% year-on-year, driven by growing sales volumes. Operating cash outflows fell by $2.1 million compared to the prior quarter, reflecting tighter cost control and the impact of the tax incentive. The company continues to prioritise investment in sales expansion across markets such as Spain, Germany, Italy, Greece, and Israel, alongside regulatory and manufacturing initiatives.
These financial and operational advances follow a period of regulatory and market challenges, including the suspension of OncoSil’s OSLOE securities earlier in 2026, which affected a subset of its capital structure but not the main ASX-listed shares. The company’s recent capital raising and executive remuneration restructuring echo earlier moves by CEO Nigel Lange to align management incentives with shareholder interests and cost efficiency.
Bottom Line?
OncoSil’s robust sales growth and advancing clinical programs position it for potential regulatory and commercial inflection points in FY26 and FY27, but success hinges on trial outcomes and market uptake of new delivery methods.
Questions in the middle?
- Will the TRIPP-FFX trial results support label expansion and boost commercial adoption?
- How will the new Sydney manufacturing facility impact cost of goods sold and supply reliability?
- Can the percutaneous delivery method in the PANCOSIL study accelerate clinician adoption beyond current markets?